Osteosarcoma and interferon

Brosjö, Otte

doi:10.3109/17453678909154176

Cited by 11 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although long-term benefits are still unclear, the studies conducted with IFN-a after surgery provide a blueprint of possible value for early use of a cytokine in a clinically relevant stage (68). Studies with nude mice suggest an important effect on tumor cell differentiation (69). Another model that may serve as a guideline for future studies is primary high-risk malignant melanoma, a neuroendocrine malignancy.…”

Section: Regression Of Established Tumorsmentioning

confidence: 99%

Cytokine therapeutics: lessons from interferonalpha.

Gutterman

1994

Proc. Natl. Acad. Sci. U.S.A.

638

356

View full text Add to dashboard Cite

Cytokines are soluble proteins that allow for communication between cells and the external environment.Interferon (IFN) a, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator ofgrowth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. This review focuses on the biological and clinical activities of the cytokine. Originally discovered as an antiviral substance, the efficacy of IFN-a in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. The principles learned from in vivo studies will be discussed, particulady hairy cell leukemia, chronic myelogenous leukemia, certain angiogenic diseases, and hepatitis. After the surprising discovery of activity in a rare B-cell neoplasm, IFN-a emerged as a prototypic tumor suppressor protein that represses the dinhl tumorigenic phenotype in some malgancies capable of differentiation. Regulatory agencies throughout the world have approved IFN-a for treatment of 13

show abstract

Section: Regression Of Established Tumorsmentioning

confidence: 99%

Cytokine therapeutics: lessons from interferonalpha.

Gutterman

1994

Proc. Natl. Acad. Sci. U.S.A.

638

356

View full text Add to dashboard Cite

show abstract

“…Direct antitumour activity in osteosarcoma has been demonstrated in vitro (Strander and Einhorn, 1977;Dannecker et al, 1985) and in vivo (Masuda et al, 1983;Hofmann et al, 1985; J Cancer Sci Ther Volume 2(1) : 016-025 (2010) -017 ISSN:1948-5956 JCST, an open access journal Brosjo, 1989). Pioneering work at the Karolinska Hospital in Stockholm strongly indicated single agent activity of adjuvant human IFN-α in patients with non metastatic high-grade osteosarcoma (Muller et al, 2005;Strander, 2007).…”

Section: Introductionmentioning

confidence: 99%

Characterization of Treatment Response to Recombinant Interferon-a2b in Osteosarcoma Xenografts

et al. 2010

View full text Add to dashboard Cite

Interferons (IFNs) may target cancer cells both through their regulation of the immune response, effect on angiogenesis and through direct effect on cancer cells. Treatment response has been demonstrated in osteosarcoma patients, but tumour resistance to IFN-α is common. Hence, understanding the molecular mechanisms involved in response and resistance is essential for improving therapeutic efficacy. Of five xenografts screened for specific growth delay in response to treatment with unconjugated and PEGylated IFN-α2b, one displayed growth inhibition and tumour shrinkage. Growth inhibition increased on a dosing schedule of PEGylated IFN every third day. Xenografts resistant to PEGylated IFN were similarly resistant to unconjugated IFN. Combination treatment with IFN-α2b and doxorubicin resulted in improved growth control rates. Transcriptional profiling analysis of the one sensitive and two resistant xenografts identified a common set of 79 genes significantly affected by IFN-α2b treatment independent of tumour growth inhibition. All but four of the 79 genes were up-regulated. The majority of these genes were well characterized IFN-stimulated genes and core members of the IFN-α signalling pathway. The expression of a set of 128 unique genes changed only in the sensitive xenograft; 52/128 genes were up-regulated. The specific geneexpression pattern seen in the responsive xenograft identified possible pathways important for the antitumor effect of IFN-α in osteosarcoma, including ssubsets of genes involved in cell adhesion and osteogenic tissue development. The observed improved control rates of combined treatment with IFN and doxorubicin are encouraging and should be further explored.

show abstract

Current status of DNA cytometry in osteosarcoma

Bauer

1993

Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies

View full text Add to dashboard Cite

Osteosarcoma and interferon

Cited by 11 publications

References 70 publications

Cytokine therapeutics: lessons from interferonalpha.

Cytokine therapeutics: lessons from interferonalpha.

Characterization of Treatment Response to Recombinant Interferon-a2b in Osteosarcoma Xenografts

Current status of DNA cytometry in osteosarcoma

Contact Info

Product

Resources

About